



PRESS RELEASE
05 May 2022 16:10:00 CEST

A3P Biomedical has successfully completed a Private Placement of SEK 400 million

A3P Biomedical AB (publ) (“A3P Biomedical” or the “Company”), a Swedish company that specializes in advanced prostate cancer diagnostics, has successfully completed a private placement of shares (the “Private Placement”) of SEK 400 million. The purpose of the Private Placement is to finance the Company’s growth strategy and accelerate the commercialization of Stockholm3, as well as to broaden the investor base.

“We welcome the new shareholders in A3P Biomedical and are very happy and proud to have completed a successful private placement of SEK 400 million in a volatile financial market. It is a quality stamp which confirms the confidence in A3P Biomedical and our product Stockholm3. We now have the financial muscles needed to accelerate our global growth with the aim of generating long-term value both for society and our shareholders”, says David Rosén, CEO of A3P Biomedical.

The Board of Directors of A3P Biomedical has, with support from the authorization granted by the Annual General Meeting held on 22 June 2021, decided to complete a SEK 400 million private placement. The Board has also decided on a directed share issue to existing shareholders at a maximum value of approximately SEK 40 million, and further information will shortly be sent to the Company’s shareholders. The purpose of these share issues is to finance the Company’s growth strategy and accelerate the commercialization of Stockholm3 – a blood test for early detection of prostate cancer – as well as to broaden the shareholder base.

The Board has used the authorization by the annual general meeting to direct the first portion of the share issue to a few long-term shareholders with strong capital resources and extensive industrial experience which, for A3P Biomedical and thus for its shareholders, was considered to be the most favorable way of raising the desired capital. Concurrently, the Board has seen to the best interests of existing shareholders and decided on a directed share issue to them, in accordance with the existing shareholders’ agreement, as a complement to the Private Placement.

Advisers

Carnegie Investment Bank AB (publ) acted as sole financial adviser to A3P Biomedical.
Advokatfirman Vinge KB acted as legal adviser to A3P Biomedical.

- (1) Thomas von Koch and Christian Kinch via TomEq Private AB, KinKon AB and KK Invest AB.
- (2) Via Inbox Investment AB and Inbox Intressenter 5 AB.

A3P Biomedical AB (publ)



For additional information, please contact:

David Rosen, CEO
Telephone: +46 10 1823325
Email: david.rosen@a3p.com

About A3P Biomedical

A3P Biomedical's mission is to improve quality of life of men by radically increasing the precision in prostate cancer diagnostics. The company's lead product is **Stockholm3**, a blood test for early detection of aggressive prostate cancer. Stockholm3 has been developed by scientists at Karolinska Institutet and validated in clinical studies including more than 75,000 men. A total of SEK 750 million has been invested in clinical research, product development and market validation activities of Stockholm3. A3P Biomedical is headquartered in Stockholm, Sweden. For more information, please visit www.a3p.com.

About Stockholm3

Stockholm3 is a blood test that combines protein markers, genetic markers, clinical data, and a proprietary algorithm, to predict the risk of aggressive prostate cancer at an early stage. In clinical practice, Stockholm3 finds 100 percent more aggressive prostate cancers and reduces 50 percent of unnecessary biopsies compared to current practice with PSA (3).

Stockholm3 has been evaluated in clinical studies with more than 75,000 men. Data from the latest pivotal study, a randomized study including 12,750 men, was published in The Lancet Oncology in 2021. Multiple studies have been published in high-impact journals, including a previous study with 58,000 men, published in The Lancet Oncology in 2015 (3).

Based on robust peer-reviewed clinical data, leading Nordic healthcare providers such as Capio S:t Görans Hospital in Sweden and Stavanger University Hospital in Norway have replaced PSA with Stockholm3. Patients benefit from a more precise test (increasing sensitivity and specificity) and healthcare providers can reduce the direct costs by 17 to 28 percent (3).

(3) Publications, results and clinical validation.

About prostate cancer

Prostate cancer is the second most common male cancer, and the fifth leading cause of cancer related death in men worldwide. According to WHO, 1.4 million men were diagnosed with prostate cancer and 375,000 deaths were reported in 2020. Incidence of prostate cancer is expected to increase by 70 percent until 2040, driven by an aging population.

A3P Biomedical AB (publ)



Attachments

[A3P Biomedical has successfully completed a Private Placement of SEK 400 million](#)